Real-World data reveals how dapagliflozin works for kidney disease

NCT ID NCT07450820

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed observational study analyzed electronic health records of nearly 13,000 adults with chronic kidney disease in Spain to see how the drug dapagliflozin is used in everyday practice. Researchers looked at patient characteristics, lab results, and healthcare costs over 39 months. The goal was to understand treatment patterns and outcomes, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dapagliflozin

What this could lead to

If successful, this study could provide real-world evidence on how dapagliflozin is used and its effectiveness in managing chronic kidney disease in routine clinical practice.

What could go wrong

As an observational study, it cannot prove cause and effect. Results may be influenced by factors like patient selection or data quality, and may not apply to all CKD patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Madrid, 28002, Spain